Just a few short years ago, Williston, North Dakota, was a sleepy little agricultural town with a population of less than 15,000. But thanks to a recent economic boom, Williston has quickly become one of the most fascinating places on the planet. People in this little town… Read More

The investing phrase “Growth at a Reasonable Price,”  or GARP for short, likely sums up the ideal backdrop for many investors. Yet many stocks right now appear to possess fairly dim growth prospects and really only appeal to value-oriented investors. Indeed, I added toy maker Hasbro (NYSE: HAS) to… Read More

A key challenge in the pharmaceutical industry these days is the staggering amount of drugs losing their patent protection. Back in November 2011, Pfizer’s (NYSE: PFE) Lipitor — the company’s all-time best-selling drug, which reported annual sales in excess of $10 billion at its peak — lost its patent protection. Read More

There’s nothing like being burned by an investment, and those with money in emerging market stocks learned about it the hard way in 2011. As a group, emerging markets plunged nearly 19%, making them one of the worst-performing… Read More

It was bound to happen. When I first began looking at stocks to add to my $100,000 Real-Money Portfolio, I knew I’d eventually come to a crossroads where I might have a holding that didn’t quite turn out how I’d hoped (or at least not yet), and I’d be faced… Read More

Every few weeks, another major manufacturer announces plans to shut down production in China and bring jobs closer to home. Some companies such as GE (NYSE: GE) aim to boost production in the United States (GE will make hot water heaters in Kentucky, for example). That’s because China is no… Read More

How would you like to own a company that is GUARANTEED to sell everything it can produce? You could charge any price for your product and it wouldn’t matter. The world is so desperate for what your selling it will pay ANYTHING to get its hands on… Read More

Analysts aren’t always right. They’re not always timely either. But when they’re in consensus about a stock, especially when that opinion is bearish (analysts are notoriously rosy with their outlooks), then there’s a good chance their collective opinion is on target, and investors… Read More

I’ve been thinking about biotech stocks a great deal lately. The sector seems to be trading much better in the early weeks of 2012, with a few spectacular gainers already in the bag and likely more to come. Yet investors are also well aware many biotech stocks simply flame out… Read More

The appeal of investing in turnaround stocks is very compelling. Some companies look to revamp products to re-invigorate sales growth. Others find ways to slash expenses and unlock major profit-margin gains. Still, others look to clean up a debt-laden… Read More